News & Insights Search

President Donald Trump on Tuesday confirmed that Marty Makary, Commissioner of the US Food and Drug Administration (FDA), is leaving the agency. He also announced on Truth Social that Kyle Diamantas, who currently serves as FDA deputy commissioner for food, will step up as acting FDA commissioner.

The US Food and Drug Administration (FDA) is asking for input on repurposing older drugs for new therapeutic uses to address unmet medical needs across a wide range of therapeutic areas.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

LISBON – Industry representatives, patients, and regulators shared their perspectives on the reforms to the EU pharmaceutical legislation at RAPS Euro Convergence 2026. The panelists noted that many challenges remain as lawmakers and regulators work to implement the law but expressed hope that it will bring much-needed improvements to the EU regulatory system.

The US Food and Drug Administration (FDA) has finalized guidance to assist sponsors in evaluating drug safety during pregnancy after a drug has been approved. The purpose of these safety studies is to gather information that can be included in drug labeling, which will help healthcare providers and patients make informed decisions.

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) has begun piloting a fast-track registration pathway for products authorized in the European Union or United States.

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. Multiple outlets reported that FDA Commissioner Marty Makary is being pushed out at FDA, though it is unclear how or when the departure will take place.

The US Food and Drug Administration (FDA) has released a final guidance document with immediate effect advising sponsors on chemistry, manufacturing, and controls (CMC) flexibilities for cell and gene therapy (CGT) products developed for biologics license applications (BLAs).

LISBON – Regulators and industry representatives highlighted the importance of simplifying regulations to promote innovation at the RAPS Euro Convergence 2026 conference closing plenary; however, they cautioned that oversimplification could backfire and lead to more regulation down the road.

Officials from the US Food and Drug Administration (FDA) discussed the launch of a new artificial intelligence (AI) system to consolidate 40 different application data sources across all centers at the Food and Drug Law Institute’s (FDLI) Annual Meeting on Thursday.

LISBON – Orphan medical device makers should be deliberate in their questions to expert panels and ensure their post-market clinical follow-up (PMCF) plan is realistic, according to experts who spoke at RAPS Euro Convergence 2026 on Thursday.